Program
neridronic acid
Also written as “Neridronate”, “Neridronic acid 100 mg” and “Neridronic acid”.
Its studies are mostly in Complex Regional Pain Syndromes · Reflex Sympathetic Dystrophy, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Grünenthal | 40 open or running | phase 3since Mar 25, 2015 | Mar 25, 2015 | none ahead |
| Ambros Therapeutics | 22 open or running | phase 3since Sep 17, 2025 | Sep 17, 2025 | Dec 2027phase 3 · NCT07210515 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 25, 2015First study: phase 3 study in Reflex Sympathetic DystrophyNew to GrünenthalGrünenthal · NCT02402530 · 459 enrolled · United States, Germany, United Kingdom
- Nov 21, 2016Phase 3 study in Complex Regional Pain SyndromesGrünenthal · NCT02972359 · 580 enrolled · United States, Germany
- May 7, 20182 phase 3 studies in Complex Regional Pain SyndromesGrünenthal · NCT03560986, NCT03530345
- Sep 17, 2025Ambros Therapeutics's first study: phase 3 study in Complex Regional Pain SyndromesNew to Ambros TherapeuticsAmbros Therapeutics · NCT07210515 · 270 planned · United States
- Sep 24, 2026Phase 3 study in Complex Regional Pain SyndromesAmbros Therapeutics · NCT07857733 · 135 planned · United States
Ahead
- Dec 2027Primary completion: phase 3 study in Complex Regional Pain SyndromesAmbros Therapeutics · NCT07210515
- Dec 31, 2028Primary completion: phase 3 study in Complex Regional Pain SyndromesAmbros Therapeutics · NCT07857733
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07857733Complex Regional Pain Syndromes · United States | 3 | Recruiting | Ambros Therapeutics | Dec 31, 2028 | 135 |
| NCT07210515Complex Regional Pain Syndromes · United States | 3 | Recruiting | Ambros Therapeutics | Dec 2027 | 270 |
| NCT03560986Complex Regional Pain Syndromes · United States, Canada, Czechia and more | 3 | Terminated | Grünenthal | Aug 1, 2019 | 267 |
| NCT03530345Complex Regional Pain Syndromes · United States, Australia, France and more | 3 | Terminated | Grünenthal | Jul 31, 2019 | 182 |
| NCT02972359Complex Regional Pain Syndromes · United States, Germany | 3 | Completed | Grünenthal | Jan 9, 2019 | 580 |
| NCT02402530Reflex Sympathetic Dystrophy · United States, Germany, United Kingdom | 3 | Completed | Grünenthal | Aug 2016 | 459 |
How it is read
Names in the registry
- “Neridronate”, 2 entries
- “Neridronic acid 100 mg”, 2 entries
- “Neridronic acid”, 1 entry
- “Neridronic acid 62.5 mg”, 1 entry
Conditions, from the studies’ own filings
- Complex Regional Pain Syndromes, 4 studies
- Reflex Sympathetic Dystrophy, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.